Lawrence Schachner, MD, discusses recent developments in the pediatric atopic dermatitis treatment landscape, including:
Can you share some advice for dermatologists on communicating with parents and caretakers of pediatric AD patients regarding treatment options and at-home interventions?
Dupilumab is currently approved for patients with atopic dermatitis aged 6 years and older. Do you foresee dupilumab being approved for even younger patients in the near future?
How do emerging JAK inhibitors fit into the existing treatment landscape for pediatric patients with atopic dermatitis?
